There is no 100% consensus for reform in the US
Although there is much talk of US patent reform at the moment, it is worth remembering that not everyone is keen for it to happen. This blog has already had a look at the differences that exist between the large high-tech and pharma companies over…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.